论文部分内容阅读
目的:对比研究阿莫西林与阿莫西林-克拉维酸钾不良反应。方法:选取我院2007-2011年收治的采用阿莫西林与阿莫西林-克拉维酸钾治疗的326例患者,其中,男性183例,年龄在15-57岁之间,女性143例,年龄在19-64岁之间。所有有患者均经临床诊断为感染性疾病。将其随机分为两组,A组163例,B组163例,A组患者采用阿莫西林进行治疗,B组患者采用阿莫西林-克拉维酸钾进行治疗,对两组患者产生的不良反应进行对比分析,并记录所得数据。结果:经过治疗发现,两组患者都产生了一定程度的不良反应,A组163例患者中,过敏反应101例,占62%;泌尿系统不良反应12例,占7.4%;神经系统不良反应17例,占10.4%;消化系统不良反应19例,占11.7%;循环系统不良反应8例,占4.9%;其他不良反应6例,占3.7%。B组163例患者中,泌尿系统不良反应83例,占50.9%;过敏反应39例,占23.9%;循环系统不良反应41例,占25.2%。结论:临床在治疗感染性疾病时,采用阿莫西林-克拉维酸钾治疗的安全性要显著优于采用阿莫西林治疗,对于促进患者病情的快速改善和生活质量的提高有更大的帮助。
Objective: To compare the adverse effects of amoxicillin and amoxicillin-clavulanate potassium. Methods: A total of 326 patients treated with amoxicillin and amoxicillin-clavulanate potassium in our hospital from 2007 to 2011 were selected, including 183 males, aged 15-57 years, 143 females, Between 19-64 years old. All patients were clinically diagnosed as infectious diseases. They were randomly divided into two groups: 163 cases in group A and 163 cases in group B, the patients in group A were treated with amoxicillin, the patients in group B were treated with amoxicillin and clavulanate potassium, The reaction was analyzed comparatively and the data recorded. Results: A total of 101 adverse reactions occurred in 163 patients in group A (62%), 12 in urinary system (7.4%), nervous system adverse reactions Cases, accounting for 10.4%; digestive adverse reactions in 19 cases, accounting for 11.7%; circulatory system adverse reactions in 8 cases, accounting for 4.9%; other adverse reactions in 6 cases, accounting for 3.7%. Among 163 patients in group B, 83 cases were urinary system adverse reactions (accounting for 50.9%), 39 cases were allergic reactions (23.9%), and 41 cases were circulatory system adverse reactions (25.2%). CONCLUSIONS: The safety of amoxicillin-clavulanate potassium in clinical treatment of infectious diseases is significantly better than that of amoxicillin treatment, which is more helpful to promote rapid improvement of patients’ condition and improvement of quality of life .